ImageBiopsy Lab
Vienna
About ImageBiopsy Lab
ImageBiopsy Lab (IBL) is the global leader in developing and certifying state-of-the-art AI-based software for image analyses and workflow tasks in musculoskeletal (MSK) radiology, orthopaedic surgery and traumatology. Our deep tech platform has been built to automatically read and prioritize the large numbers of low-risk, low reimbursement plainfilm MSK X-rays, thus freeing valuable physician resources and significantly reducing manual reporting steps. Our ultimate mission is to cover all clinically relevant MSK/orthopaedic use cases – from low-risk plain film X-ray to complex MRI/CT. For that purpose we have established strong ties with leading US/EU medical institutions in order to provide us with an ever-growing number of training data, expert-annotators & validation resources, thus enabling us to expand our platform from plain film X-ray to MRI and CT. IBL has offices in Europe and the US and has a growing number of distinct AI-modules in FDA/CE and research-only certification stages, covering a large portion of the most common MSK-X-ray use cases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2023)
- Website: imagebiopsy.com
- Phone: +439051206
Industries & Categories
Artificial Intelligence (AI), Health Care, Health Diagnostics, Image Recognition, Machine Learning
Social Profiles
Canonical: https://fsome.com/organization/imagebiopsy-lab-76865 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.